Assessment of Combined Therapy of Histochrome and Nebivalol as Angioprotectors on the Background of Experimental Hypertension by Magnetic Resonance Angiography

Irina G. Agafonova, Vladimir N. Kotelnikov, Boris I. Geltser, Natalya G. Kolosova, Valentin A. Stonik

Результат исследования: Научные публикации в периодических изданияхстатья

2 Цитирования (Scopus)

Аннотация

The renovascular model of arterial hypertension (AH) was induced in Wistar and OXYS strains. The model of AH was verified by magnetic resonance angiography. It was shown that histochrome enhances the vasodilatory effect of selective beta1 blocker, nebivalol, against cerebral and renal arteries using a combined therapy in this model. Monotherapy with histochrome had no significant effect on blood pressure. The angioprotective effect of histochrome in the combined therapy was significantly more expressed in hypertensive OXYS rats compared to hypertensive Wistar rats as shown by magnetic resonance imaging (MRI) morphometry. These differences were more observable in the intrarenal part of renal arteries. The degree of regional discirculation of arteries was calculated by the Cerebro-Renal Vascular Index, which confirms the therapeutic advantage of combined therapy with histochrome and nebivalol in the background of AH. Thus, comparative MRI angiography and MRI morphometry of the cerebral and renal arteries in hypertensive Wistar and OXYS strain rats showed that histochrome expands the therapeutic potential of nebivalol due to angioprotective effects in the vascular region of the target organs.

Язык оригиналаанглийский
Страницы (с-по)217-225
Число страниц9
ЖурналApplied Magnetic Resonance
Том49
Номер выпуска2
DOI
СостояниеОпубликовано - фев 2018

Fingerprint Подробные сведения о темах исследования «Assessment of Combined Therapy of Histochrome and Nebivalol as Angioprotectors on the Background of Experimental Hypertension by Magnetic Resonance Angiography». Вместе они формируют уникальный семантический отпечаток (fingerprint).

  • Цитировать